A Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
Latest Information Update: 27 Oct 2023
At a glance
- Drugs HIP 2105 (Primary) ; RLD 2104
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 23 Oct 2023 Status changed from recruiting to completed.
- 29 Jul 2021 New trial record